MicroRNAs as Regulators of Neuroinflammation in Major Depressive Disorder.
Saved in:
| Title: | MicroRNAs as Regulators of Neuroinflammation in Major Depressive Disorder. |
|---|---|
| Authors: | Li, Qirui (AUTHOR), Ling, Yuyan (AUTHOR), Gu, Ling (AUTHOR), Li, Lei (AUTHOR), Liu, Yutong (AUTHOR), Ma, Yuanyuan (AUTHOR), Ma, Ruiting (AUTHOR), Chen, Meijuan (AUTHOR), Asif, Muhammad (AUTHOR) |
| Source: | Depression & Anxiety (1091-4269). 12/11/2025, Vol. 2025, p1-20. 20p. |
| Subjects: | MicroRNA, Neuroinflammation, Blood-brain barrier, Drug target, Cytokines, Neuroplasticity, Bioactive compounds, Mental depression |
| Abstract: | Major depressive disorder (MDD) is a globally prevalent mental health condition with a complex pathogenesis and substantial disease burden. However, due to incomplete mechanistic understanding, existing therapeutic strategies frequently yield suboptimal outcomes. This review synthesizes evidence establishing neuroinflammation as a central pathogenic mechanism of MDD, involving elevated proinflammatory cytokines, microglial M1 polarization, blood–brain barrier (BBB) disruption, hypothalamic–pituitary–adrenal (HPA) axis dysregulation, and impaired neuroplasticity. Micro ribonucleic acid (miRNA) are identified as master molecular regulators bridging neuroinflammation and MDD pathology with details of how specific dysregulated miRNAs orchestrate MDD processes by targeting key inflammatory pathways, directing microglial polarization states, mediating intercellular communication via exosomes, and modulating BBB integrity. Crucially, these miRNAs may serve as novel diagnostic biomarkers and therapeutic targets for MDD. Building on this, we explore the potential of natural compounds as innovative miRNA‐targeting therapeutics that can ameliorate neuroinflammation and restore neuroplasticity. Current challenges relating to clinical translation are discussed, including discordance between peripheral and brain miRNA profiles, species‐specific miRNA functional variations, limited biomarker specificity across psychiatric disorders, the absence of standardized clinical reference ranges, and the need for more effective delivery systems. Overall, this review positions miRNA‐mediated neuroinflammation regulation as a transformative frontier for MDD pathogenesis research and targeted treatment. [ABSTRACT FROM AUTHOR] |
| Copyright of Depression & Anxiety (1091-4269) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Major depressive disorder (MDD) is a globally prevalent mental health condition with a complex pathogenesis and substantial disease burden. However, due to incomplete mechanistic understanding, existing therapeutic strategies frequently yield suboptimal outcomes. This review synthesizes evidence establishing neuroinflammation as a central pathogenic mechanism of MDD, involving elevated proinflammatory cytokines, microglial M1 polarization, blood–brain barrier (BBB) disruption, hypothalamic–pituitary–adrenal (HPA) axis dysregulation, and impaired neuroplasticity. Micro ribonucleic acid (miRNA) are identified as master molecular regulators bridging neuroinflammation and MDD pathology with details of how specific dysregulated miRNAs orchestrate MDD processes by targeting key inflammatory pathways, directing microglial polarization states, mediating intercellular communication via exosomes, and modulating BBB integrity. Crucially, these miRNAs may serve as novel diagnostic biomarkers and therapeutic targets for MDD. Building on this, we explore the potential of natural compounds as innovative miRNA‐targeting therapeutics that can ameliorate neuroinflammation and restore neuroplasticity. Current challenges relating to clinical translation are discussed, including discordance between peripheral and brain miRNA profiles, species‐specific miRNA functional variations, limited biomarker specificity across psychiatric disorders, the absence of standardized clinical reference ranges, and the need for more effective delivery systems. Overall, this review positions miRNA‐mediated neuroinflammation regulation as a transformative frontier for MDD pathogenesis research and targeted treatment. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 10914269 |
| DOI: | 10.1155/da/9984291 |
